PHK
SYRE icon

Point72 Hong Kong’s Spyre Therapeutics SYRE Stock Holding History

Point72 Hong Kong’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-157
Closed -$9K – 2385
2022
Q1 		$9K Buy
157
+151
+2,517% +$12.7K ﹤0.01% 1622
2021
Q4 		$1K Buy
+6
New +$947 ﹤0.01% 1812
2021
Q1 		– Sell
-1
Closed – – 2201
2020
Q4 		$0 Sell
1
-51
-98% -$10.6K ﹤0.01% 2036
2020
Q3 		$9K Buy
+52
New +$9.62K ﹤0.01% 1010
2018
Q4 		– Sell
-61
Closed -$15K – 1190
2018
Q3 		$15K Buy
61
+40
+190% +$9.34K 0.01% 623
2018
Q2 		$6K Buy
+21
New +$5.17K ﹤0.01% 699

Other funds holding SYRE

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Hong Kong's SYRE Position: Q2 2022 in Review

Point72 Hong Kong sold out of Spyre Therapeutics (SYRE) in Q2 2022, closing a stake of 157 shares — an estimated $9K sold.

Point72 Hong Kong first reported a position in SYRE in Q2 2018 and held it in 6 quarters. The position peaked at $15K in Q3 2018. 66 funds tracked by Wall St. Rank hold SYRE as of Q2 2022.

  • Point72 Hong Kong reported no remaining Spyre Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 157 Spyre Therapeutics shares in Q2 2022, an estimated $9K.
  • Point72 Hong Kong first reported a position in Spyre Therapeutics in Q2 2018 and held it in 6 quarters.
  • Point72 Hong Kong's Spyre Therapeutics position peaked at $15K in Q3 2018.
  • 66 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.